As per Regulation 34 of of SEBI (Listing Obligations and Disclosure requirement) Regulations, 2015: Annual Report for the Financial year ending 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India has filed its Annual Report for FY ending 31st March 2025 and the notice for its 32nd AGM, scheduled for 4th September 2025 at 3:30 PM via video conferencing. Shareholders will vote on adopting the audited financial statements, re-appointing director Mr. Suninder Veer Singh (retiring by rotation), and re-appointing M/s STAV & Co as statutory auditors for a 5-year term through FY 2030-31. The company is seeking shareholder approval for material related party transactions for FY 2026-27, including up to Rs 1,000 crore with Pharmacare International and Rs 100 crore each with Indosol Export and JB Khokhani & Co. It is also seeking ratification of a Rs 50 crore corporate guarantee issued on behalf of Pharmacare International. Other items include approval of cost auditor remuneration (Rs 45,000) and appointment of Mr. Kanwaljit Singh Thanewal as secretarial auditor for 5 years. E-voting will run from 1st to 3rd September 2025, with the cut-off date set as 28th August 2025.
The large proposed related party transaction limit of Rs 1,000 crore with Pharmacare International is notable and signals heavy business dependence on promoter-linked entities, which shareholders should evaluate carefully. Otherwise, this is a routine annual report filing with standard governance items requiring approval.